Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -129.90% is 31% above its 5-year average of -186.95%, near the high end of its 5-year range (-1396.04%–-13.86%).
As of the fiscal period ended Tuesday, June 30, 2026. 77.11% above its 12-month average of -567.56%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -129.90%.
RETURN ON INVESTED CAPITAL (ROIC)
-129.90%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-567.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-284.73%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-186.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-128.02%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+77.11%
CURRENT VS 3Y AVG
+54.38%
CURRENT VS 5Y AVG
+30.52%
CURRENT VS 10Y AVG
-1.47%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.61%
median of 724 covered companies
CURRENT VS SECTOR MEDIAN
-286.43%
vs the sector median at left
Indaptus Therapeutics, Inc.
Market Cap
$285.37M
Return on Invested Capital (ROIC)
-129.90%
TTM Avg
-567.56%
3Y Avg
-284.73%
5Y Avg
-186.95%
Market Cap
$287.55M
Return on Invested Capital (ROIC)
-49.76%
TTM Avg
-54.76%
3Y Avg
-73.23%
5Y Avg
-84.98%
Market Cap
$288.15M
Return on Invested Capital (ROIC)
-20.40%
TTM Avg
-43.02%
3Y Avg
-57.92%
5Y Avg
-48.43%
Market Cap
$282.68M
Return on Invested Capital (ROIC)
-27.62%
TTM Avg
-16.38%
3Y Avg
-32.77%
5Y Avg
-39.71%
Market Cap
$288.27M
Return on Invested Capital (ROIC)
-14.06%
TTM Avg
-26.07%
3Y Avg
-28.37%
5Y Avg
-26.89%
Market Cap
$288.34M
Return on Invested Capital (ROIC)
-61.10%
TTM Avg
-38.45%
3Y Avg
-31.16%
5Y Avg
-81.63%
Market Cap
$279.05M
Return on Invested Capital (ROIC)
-15.69%
TTM Avg
-4.06%
3Y Avg
-9.73%
5Y Avg
-12.88%
Market Cap
$277.96M
Return on Invested Capital (ROIC)
-31.62%
TTM Avg
-73.81%
3Y Avg
-69.44%
5Y Avg
-42.80%
Market Cap
$275.66M
Return on Invested Capital (ROIC)
-58.72%
TTM Avg
-52.25%
3Y Avg
-49.23%
5Y Avg
-41.07%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $285.37M | -129.90% | -567.56% | -284.73% | -186.95% |
| Abeona Therapeutics Inc. (ABEO)vs › | $287.55M | -49.76% | -54.76% | -73.23% | -84.98% |
| Sagimet Biosciences Inc. (SGMT)vs › | $288.15M | -20.40% | -43.02% | -57.92% | -48.43% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.68M | -27.62% | -16.38% | -32.77% | -39.71% |
| Standard BioTools Inc. (LAB)vs › | $288.27M | -14.06% | -26.07% | -28.37% | -26.89% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $288.34M | -61.10% | -38.45% | -31.16% | -81.63% |
| Aurora Cannabis Inc. (ACB)vs › | $279.05M | -15.69% | -4.06% | -9.73% | -12.88% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.96M | -31.62% | -73.81% | -69.44% | -42.80% |
| Fate Therapeutics, Inc. (FATE)vs › | $275.66M | -58.72% | -52.25% | -49.23% | -41.07% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.61M | -136.49% | -130.82% | -85.38% | -76.42% |
ROIC
-129.9%
ROE
-135.6%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -129.90% |
| 2026-03-31 | -1396.04% |
| 2025-12-31 | -629.32% |
| 2025-09-30 | -344.12% |
| 2025-06-30 | -338.42% |
| 2025-03-31 | -571.31% |
| 2024-12-31 | -389.51% |
| 2024-09-30 | -255.92% |
| 2024-06-30 | -266.08% |
| 2024-03-31 | -168.59% |
| 2023-12-31 | -134.80% |
| 2023-09-30 | -105.55% |
| 2023-06-30 | -83.18% |
| 2023-03-31 | -74.87% |
| 2022-12-31 | -60.54% |
| 2022-09-30 | -50.93% |
| 2022-06-30 | -45.53% |
| 2022-03-31 | -31.48% |
| 2021-12-31 | -21.49% |
| 2021-09-30 | -13.86% |
| 2021-06-30 | -23.60% |
| 2020-09-30 | -43.03% |
| 2020-06-30 | -98.59% |
| 2020-03-31 | -154.48% |
| 2019-12-31 | -259.20% |
| 2019-09-30 | -220.72% |
| 2019-06-30 | -113.82% |
| 2019-03-31 | -92.98% |
| 2018-12-31 | -80.45% |
| 2018-09-30 | -63.26% |
| 2018-06-30 | -53.21% |
| 2018-03-31 | -72.34% |
| 2017-12-31 | -50.06% |
| 2015-12-31 | -21.14% |
